Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging Immunotargets in Bladder Cancer.
Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A. Massari F, et al. Among authors: scarpelli m. Curr Drug Targets. 2016;17(7):757-70. doi: 10.2174/1389450117666160201105537. Curr Drug Targets. 2016. PMID: 26844572
Bladder cancer: molecular determinants of personalized therapy.
Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Lopez-Beltran A, et al. Among authors: scarpelli m. Curr Drug Targets. 2015;16(2):115-24. doi: 10.2174/1389450116666150204115756. Curr Drug Targets. 2015. PMID: 25654736 Review.
Emerging Immunotargets in Metastatic Renal Cell Carcinoma.
Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Holger M. Kucharczyk J, et al. Among authors: scarpelli m. Curr Drug Targets. 2016;17(7):771-6. doi: 10.2174/1389450117666151209115753. Curr Drug Targets. 2016. PMID: 26648075 Review.
An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. Montironi R, et al. Among authors: scarpelli m. Curr Drug Targets. 2016;17(7):750-6. doi: 10.2174/1389450117666151209144649. Curr Drug Targets. 2016. PMID: 26648079 Review.
Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Montironi R, et al. Among authors: scarpelli m. Curr Drug Targets. 2016;17(7):777-82. doi: 10.2174/1389450117666160217123304. Curr Drug Targets. 2016. PMID: 26898309 Review.
Editorial: Emerging Immunotargets in Genitourinary Tumors.
Montironi R, Santoni M, Massari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M. Montironi R, et al. Among authors: scarpelli m. Curr Drug Targets. 2016;17(7):748-9. doi: 10.2174/138945011707160412185542. Curr Drug Targets. 2016. PMID: 27086839 No abstract available.
Tp53 and its potential therapeutic role as a target in bladder cancer.
Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca J, Lopez-Beltran A. Ciccarese C, et al. Among authors: scarpelli m. Expert Opin Ther Targets. 2017 Apr;21(4):401-414. doi: 10.1080/14728222.2017.1297798. Epub 2017 Mar 1. Expert Opin Ther Targets. 2017. PMID: 28281901 Review.
512 results